In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you'll be hearing from Ksenija Pavletic, partner and chief commercial officer at Jeito Capital and Thierry Laugel, managing partner at Kurma Partners. We dive into France’s biotech ecosystem and what still needs to happen for more early innovation to translate into investable, scalable biotech.Host<a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/jennifersmithparker/" target="_blank">⁠Jennifer C. Smith-Parker</a>, Director of Insights, BioSpaceGuests<a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/ksenijapavletic/" target="_blank">Ksenija Pavletic</a>, Partner and Chief Commercial Officer, Jeito Capital<a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/thierry-laugel-414b981/" target="_blank">Thierry Laugel</a>, Managing Partner, Kurma PartnersDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.